Iridex Corp key statistics and ratios

In fiscal 2025, Iridex Corp had return on equity of -126.4%, an operating margin of -4.9%, debt equal to 75.9% of equity and a current ratio of 1.91. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Iridex Corp: financial ratios, annual
Fiscal year	2009Jan 2010	2010Jan 2011	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Jan 2015	2015Jan 2016	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Jan 2021	2021Jan 2022	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Jan 2026	LTMJul 2026
Gross margin	49.8%	50.1%	49.1%	48.3%	48.6%	50.0%	47.8%	45.1%	37.3%	41.0%	41.3%	42.8%	42.4%	44.5%	42.0%	40.1%	36.5%	35.9%
Operating margin	4.0%	3.7%	5.8%	−2.5%	6.9%	6.0%	0.7%	−5.6%	−31.0%	−30.2%	−20.7%	−18.1%	−14.0%	−13.2%	−19.3%	−17.1%	−4.9%	−5.4%
Net margin	8.3%	9.4%	7.9%	4.2%	5.8%	23.4%	1.1%	−25.4%	−30.9%	−30.1%	−20.3%	−17.4%	−9.7%	−13.2%	−18.5%	−18.3%	−8.4%	−6.9%
Free-cash-flow margin	9.1%	2.9%	6.2%	−4.5%	1.0%	8.0%	−3.5%	−2.6%	−10.0%	−24.6%	−18.5%	−9.2%	14.8%	−17.2%	−13.2%	−15.0%	−4.3%	−3.9%
Return on equity	17.2%	17.7%	12.5%	6.5%	9.3%	33.7%	1.4%	−32.2%	−36.9%	−42.4%	−33.5%	−31.6%	−25.7%	−37.2%	−71.5%	−153.4%	−126.4%	−82.9%
Return on assets	—	10.4%	8.5%	4.7%	7.1%	26.6%	1.1%	−26.0%	−28.7%	−30.8%	−23.0%	−20.2%	−13.6%	−16.6%	−24.9%	−28.0%	−15.2%	−12.6%
Asset turnover	—	1.11	1.08	1.11	1.22	1.13	1.00	1.03	0.93	1.02	1.14	1.16	1.41	1.25	1.35	1.53	1.81	1.83
Current ratio	—	2.87	3.31	4.25	4.34	4.67	4.14	5.62	3.80	3.77	3.12	2.92	3.34	2.87	2.12	1.42	1.91	1.82
Debt to equity	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	7.2%	—	0.0%	0.0%	211.6%	75.9%	104.3%
Interest cover (operating income ÷ interest)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	n/m	n/m	—
Effective tax rate	14.5%	15.7%	12.2%	—	1.4%	—	—	—	—	—	—	—	—	—	—	—	—	—
R&D as % of revenue	10.7%	11.6%	11.8%	13.0%	9.6%	10.8%	12.5%	11.6%	12.5%	9.4%	8.5%	9.0%	12.7%	12.6%	13.2%	11.2%	7.0%	7.3%
Capital spending as % of revenue	0.6%	0.6%	0.6%	1.2%	1.0%	1.3%	2.1%	2.3%	1.4%	1.0%	0.3%	0.3%	0.4%	0.5%	0.2%	0.0%	0.3%	0.5%
Free cash flow ÷ net income	109.1%	31.0%	78.5%	−106.5%	17.3%	34.3%	−309.7%	—	—	—	—	—	—	—	—	—	—	—
Dividends and buybacks ÷ free cash flow	0.0%	0.0%	31.6%	—	110.1%	135.4%	—	—	—	—	—	—	—	—	—	—	—	—

US$ thousands unless shown otherwise. Fiscal quarters.

Iridex Corp: financial ratios, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Jan 2026	2026 Q1Apr 2026	2026 Q2Jul 2026
Gross margin	37.3%	44.0%	42.5%	34.5%	32.1%	37.2%	40.2%	34.2%
Operating margin	−16.1%	−4.0%	−1.7%	−6.9%	−11.3%	−0.1%	−2.7%	−8.2%
Net margin	−16.7%	−6.6%	−14.2%	−7.3%	−12.6%	−1.2%	−4.4%	−10.1%
Free-cash-flow margin	−26.5%	−9.8%	−9.8%	−3.0%	−9.4%	3.3%	−12.2%	1.0%
Current ratio	1.54	1.42	1.95	1.96	1.94	1.91	1.92	1.82
Debt to equity	102.9%	128.8%	427.7%	60.7%	79.1%	75.9%	79.6%	104.3%
R&D as % of revenue	11.2%	8.8%	7.4%	6.4%	7.8%	6.4%	7.7%	7.4%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

4 of 7 checks passed · July 4, 2026

What it owns · $27m

Short-term assets $24mLonger-term assets $3m

What it owes, and who funded it · $27m

Short-term liabilities $13mLonger-term liabilities $10mShareholders' equity $4m

Short-term assets cover short-term liabilities $24m of assets due within a year against $13m of liabilities due within a year.
Short-term assets cover long-term liabilities $24m short-term assets against $10m of longer-dated liabilities.
More cash than debt $5m of cash against $4m of debt.
Debt below 40% of shareholders' equity Debt is 104% of equity.
Debt burden no higher than five years ago Debt to equity moved from 1% to 104% over five years.
A year's operating cash flow covers at least 20% of debt −$2m of operating cash flow against $4m of debt.
Operating profit covers interest at least five times over No material interest expense reported.

From Iridex Corp's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

34 /100

Weak moat

How hard Iridex's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

Returns on capital 0 / 20

Cash operating profit has been a median -7.0% of total assets over 10 years.
Pricing power 14 / 20

Gross margin has been a median 41.2%, moving by 2.8 percentage points (standard deviation) across 10 years.
Durability 10 / 20

Operating margin has been a median -16.2%; its worst year was -37.1%.
Cash conversion 1 / 20

Free cash flow was positive in 1 of 10 years, at a median -12.9% of revenue.
Discipline 9 / 20

The diluted share count rose 18.0% over five years; stock-based pay has been a median 3.1% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: IRIX vs SENS APYX vs IRIX CLPT vs IRIX

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Iridex Corp's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Iridex Corp.